① What are the highlights of Innoscience's compliance supply agreement with Google? ② Simcere Pharmaceutical received a $40 million milestone payment; which pipelines have shown progress?
Cailian Press, February 3rd, by editor Feng Yi. Cailian Press brings you today’s key announcements for Hong Kong-listed stocks.
1) Corporate News
Innoscience (02577.HK): The company’s related products have completed important design integration on Google’s AI hardware platform and signed a compliant supply agreement.
The announcement stated that based on current project development and customer engagement progress, the company will focus on high-growth potential fields such as AI servers and data centers. It will actively collaborate with industry chain partners to commercially implement related products in compliance with regulations, meeting market and customer demands.
Nissin Foods (01475.HK): The controlling shareholder, Nissin Foods Holdings Co., Ltd. (Nissin Japan), reported revenue of 53.544 billion yen from its China business segment for the nine months ended December 31, 2025. Excluding exchange rate factors, revenue reached 54.948 billion yen, representing a year-on-year increase of 2.7%; core operating profit was 5.859 billion yen, up 9.3% year-on-year.
Insilico Medicine (03696.HK): Received a milestone payment of HKD 39 million from Menarini; the collaborative project MEN2501 has administered the first patient dose.
Simcere Pharmaceutical (02096.HK): Received a recent milestone payment of $40 million under the overseas licensing option agreement for SIM0500 with AbbVie.
Data Alliance Capital (08375.HK): Its Dubai subsidiary has signed a contract worth $3 million with a Macau distributor.
Shanxi Installation (02520.HK): Shanghai Jingyu and Shanxi Infrastructure have entered into a joint venture agreement to establish a joint venture company to invest in a BOO project. This project involves the construction and operation of zero-discharge wastewater facilities for Shanxi Lanhua Energy Conservation and Environmental Protection Upgrading Project, with an estimated total investment of RMB 267 million.
Capital First Holdings (00697): Its subsidiary, Shizun Shares (001220.SZ), conducted its initial public offering and listed on the Shenzhen Stock Exchange. The company focuses on providing customized, integrated, and embedded supply chain logistics solutions for multinational manufacturing enterprises.
Akeso Biopharma (09926.HK): Granted Jichuan Pharmaceutical exclusive commercialization rights for Yi Xining, and will receive an authorization fee of RMB 80 million (including tax) paid by Jichuan Pharmaceutical, as well as milestone payments of up to RMB 10 million (including tax).
Youzhiyou Bio-B (02496): M701 received FDA IND approval, marking this innovative therapy targeting malignant pleural effusion (MPE) entering a new phase of international clinical development.
Federal Pharmaceutical (03933): UBT251 Injection for OSA indication has been granted tacit approval for clinical trials.
EPS Healthtech (03860.HK): Plans to acquire 16.23% equity interest in China Gene at a consideration ranging from approximately HKD 40 million to HKD 45 million.
Country Garden (02007.HK): Contracted sales amount for January was approximately RMB 2.21 billion.
Jiahhe Biopharma (06998.HK): Proposed to change its stock abbreviation to 'Yiteng Jiahhe'.
2) Financing and Share Repurchase Updates
Xiaomi Group-W (01810.HK): Repurchased 3 million shares for HKD 104 million at a repurchase price ranging from HKD 34.62 to HKD 34.92 per share.
Yum China (09987.HK): Repurchased 20,100 shares for HKD 7.7398 million at a repurchase price ranging from HKD 382.8 to HKD 388 per share.
Yuegang Bay Holdings (01396.HK): Proposed to issue a total of 20,311,000 subscription shares at a discount of approximately 8.40%, raising net proceeds of approximately HKD 121.6 million.
